MedDataX Logo

Comparative Study of Anaconda System Use Versus Conventional Sedation in COVID-19 Patients.

NCT ID: NCT06208592

Last Updated: 2024-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

43 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-30

Study Completion Date

2020-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At the beginning of 2020, a global alert emerged which saturated intensive care units due to COVID-19 worldwide. This caused a need for mechanical ventilation due to atypical pneumonias that had a rapid evolution and respiratory failure; therefore the consumption of sedative agents in the intensive care units escalated. Suboptimal sedation in the intensive care unit, increases the adverse effects, costs, and morbidity. For the time being, they focus on the use of intravenous agents such as propofol or dexmedetomidine, which are associated with tolerance, withdrawal, delirium, and hemodynamic effects. Consequently, the need arises to maximize availability and effectiveness, which is why the intervention of the ANACONDA conservation device is carried out, which works with a heat and humidity exchange filter capable of administering isoflurane or sevoflurane with an efficiency of 90%.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AnaConDa-therapy in COVID-19 Patients

NCT05586126

COVID-19 SARS CoV-2
TERMINATED

Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2

NCT04998253

Hypoxic Pulmonary Vasoconstriction Hypoxemia Acute Respiratory Distress Syndrome +1 more
COMPLETED EARLY_PHASE1

ANALYSIS OF CLINICAL AND LABORATORY VARIABLES WITH PREDICTION CAPABILITY FOR INDICATION OF INVASIVE MECHANICAL VENTILATION IN PATIENTS WITH COVID-19

NCT05663528

COVID-19
COMPLETED

Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection

NCT06310941

Nosocomial Infection Nosocomial Pneumonia Tracheobronchitis +2 more
NOT_YET_RECRUITING NA

Pressure Support Ventilation With the Anesthetic Conserving Device

NCT01017744

Intensive Care Ventilation
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Analyze the difference in intravenous sedation requirements in patients with COVID-19. Patients who were assisted by a mechanical ventilator with sevoflurane versus conventional sedation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Respiratory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anaconda Group

Use of Anaconda devide at any point during the initial follow up (7 days) additional of conventional intravenous sedation

Sevoflurane with AnaConDa

Intervention Type DEVICE

Sevoflurane administered with AnaConDa device

Non-Anaconda Group

Use on conventional intravenous sedation, not using Anaconda device

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sevoflurane with AnaConDa

Sevoflurane administered with AnaConDa device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with confirmed COVI-19 infection and assited with mechanical ventilation who entered critical care department.

Exclusion Criteria

* Tranfers to a different hospital.
* Death within the first 24 hours of hospital stay.
Minimum Eligible Age

27 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Nacional Autonoma de Mexico

OTHER

Sponsor Role collaborator

Hospital Español de Mexico

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jose J Zaragoza, MD

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manuel Lomeli, MD

Role: STUDY_CHAIR

Hospital H+ Queretaro

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital H+ Queretaro

Querétaro City, Querétaro, Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-01-Anaconda

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.
NCT04609462 COMPLETED NA
Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina
NCT04611269 COMPLETED
Extubation Advisor: Initial Implementation and Evaluation of a Novel Extubation Clinical Decision Support Tool
NCT04708509 COMPLETED PHASE1
Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation
NCT04448782 COMPLETED
High-flow Conditioned Oxygen Therapy Versus Non-invasive Ventilation: Prevention of Post-extubation Failure
NCT01191489 COMPLETED PHASE3
Predictive Factors for Failure of Non-invasive Support Ventilation in Patients With COVID-19: A Retrospective Study.
NCT05579080 COMPLETED
Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients
NCT05363332 UNKNOWN
Respiratory Care in Intensive Care Unit for Neuromuscular Patients
NCT02936908 UNKNOWN
Tracheal Intubation in COVID-19 Patients
NCT04909476 UNKNOWN
Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19
NCT04922814 COMPLETED NA
Continuous Endotracheal Cuff Pressure Control to Prevent Ventilator Associated Respiratory Infections
NCT02966392 COMPLETED NA
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
NCT06033560 UNKNOWN
Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19
NCT05595538 COMPLETED EARLY_PHASE1
Covid-19 Airway Management
NCT04689724 COMPLETED
Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation in Patients With Hypercapnic COPD
NCT03928535 UNKNOWN NA
Early Awake Alterning Prone Positioning Combined With Non-invasive Oxygen Therapy in Patients With COVID-19.
NCT06076109 TERMINATED NA
Efects of Noninvasive Mechanical Ventilation and Conventional Mechanical Ventilation in Patients With Severe Comunity Pneumonia
NCT00523497 TERMINATED NA
Adherence to Low Tidal Volume in the Transition to Spontaneous Ventilation in Patients With Acute Respiratory Failure
NCT06042036 UNKNOWN
Biomarkers of Lung Injury in Hyperinflation in the Mechanical Ventilator Versus Manual Hyperinflation
NCT03464071 UNKNOWN NA
Prognostic Models for COVID-19 Care
NCT04689711 COMPLETED
Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.
NCT04497623 COMPLETED NA
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure
NCT04353206 TERMINATED EARLY_PHASE1
Sparing in Neuromuscular Blockade in COVID 19 ICU
NCT04459533 COMPLETED
Prospective Evaluation of Electrical Cardiometry for Hemodynamic Monitoring in COPD Patients Admitted to the Respiratory Intensive Care Unit
NCT07208578 NOT_YET_RECRUITING
Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
NCT04324528 COMPLETED NA